Cost-effectiveness of routine adolescent vaccination with an M72/AS01(E)-like tuberculosis vaccine in South Africa and India

The M72/AS01(E) tuberculosis vaccine showed 50% (95%CI: 2–74%) efficacy in a phase 2B trial in preventing active pulmonary tuberculosis disease, but potential cost-effectiveness of adolescent immunisation is unknown. We estimated the impact and cost-effectiveness of six scenarios of routine adolesce...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Rebecca C., Quaife, Matthew, Weerasuriya, Chathika, Gomez, Gabriela B., Sumner, Tom, Bozzani, Fiammetta, White, Richard G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807591/
https://www.ncbi.nlm.nih.gov/pubmed/35105879
http://dx.doi.org/10.1038/s41467-022-28234-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807591/
https://www.ncbi.nlm.nih.gov/pubmed/35105879
http://dx.doi.org/10.1038/s41467-022-28234-7

Ejemplares similares